Severe acute respiratory syndrome coronavirus 2

DGAP-News: Marinomed's Investor Relations to be Strengthened by Stephanie Kniep

Thursday, September 23, 2021 - 7:01am

Stephanie Kniep is a renowned IR Manager with more than 20 years of experience.

Key Points: 
  • Stephanie Kniep is a renowned IR Manager with more than 20 years of experience.
  • She joins Marinomed from Esprit Europe GmbH where she successfully repositioned the equity story as VP Head of Investor Relations.
  • "We are delighted to welcome Ms. Kniep as a strong support for our investor relations team.
  • "We are looking forward to working together on increasing our shareholder value with continuous, transparent and collaborative investor relations."

Valneva Continues Expansion of Clinical Trials of its Inactivated COVID-19 Vaccine Candidate VLA2001

Thursday, September 23, 2021 - 6:00am

This planned expansion of VLA2001 clinical trials will support future approval in further age groups, in addition to adults.

Key Points: 
  • This planned expansion of VLA2001 clinical trials will support future approval in further age groups, in addition to adults.
  • Valneva is conducting several clinical trials of VLA2001.
  • VLA2001 is currently the only whole virus, inactivated, adjuvanted vaccine candidate in clinical trials against COVID-19 in Europe.
  • Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need.

Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration

Wednesday, September 22, 2021 - 9:01pm

It was an honor to meet with President Nguyen Xuan Phuc and the delegation to discuss Vietnams progressive public health strategy.

Key Points: 
  • It was an honor to meet with President Nguyen Xuan Phuc and the delegation to discuss Vietnams progressive public health strategy.
  • Vietnam should be acknowledged for its thoughtful planning and aggressive actions to combat this pandemic, including its proactive approach to secure early access to vaccines targeting SARS-CoV-2 variants of concern.
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.
  • Arcturus technologies are covered by its extensive patent portfolio (231 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries).

Elicio Therapeutics Presents Updated Preclinical Data at the 2021 Vaccines Summit Demonstrating that ELI-005, a Lymph Node Targeted Amphiphile Vaccine, Induces Potent Cellular and Humoral Immunity to SARS-CoV-2

Wednesday, September 22, 2021 - 8:22pm

We are encouraged by these positive results for ELI-005 demonstrating that delivery of AMP-CpG adjuvant to the lymph nodes induces both cellular and humoral responses to SARS-CoV-2 antigens.

Key Points: 
  • We are encouraged by these positive results for ELI-005 demonstrating that delivery of AMP-CpG adjuvant to the lymph nodes induces both cellular and humoral responses to SARS-CoV-2 antigens.
  • This dual response is critical in developing broad protective immunity in patients, said Peter DeMuth, Ph.D., vice president of research at Elicio Therapeutics.
  • We believe our AMP lymph node targeted approach will produce superior clinical benefits compared to immunotherapies that do not engage the lymph nodes.
  • Elicio is engineering lymph node targeted AMPlifiers, immunomodulators, adjuvants and vaccines for an array of aggressive cancers and infectious diseases.

Reckitt, The Maker Of Lysol®, Partners With Kinsa To Build New York City's First-Ever Citywide Early Warning System For Preventable Illness

Wednesday, September 22, 2021 - 2:00pm

"Just as we have advanced warning systems for hurricanes or tornadoes, the COVID-19 pandemic has shown us just how important it is to have an early warning system for preventable illness," said Kinsa founder and CEO Inder Singh.

Key Points: 
  • "Just as we have advanced warning systems for hurricanes or tornadoes, the COVID-19 pandemic has shown us just how important it is to have an early warning system for preventable illness," said Kinsa founder and CEO Inder Singh.
  • "By growing the network of Kinsa thermometers in New York City, we're creating an illness early warning system that will help the city stop outbreaks early and ultimately save lives and livelihoods, while advancing public health across the city."
  • Kinsa's mission is to help individuals and communities stop the spread of infectious illness through early detection and early response.
  • By analyzing geographic illness trends, Kinsa quickly identifies at-risk areas and mobilizes the organizations that can help stop the spread.

Silicon Valley Bank Doubles CareCloud’s Credit Facility

Wednesday, September 22, 2021 - 2:05pm

The term of the line of credit was also extended by two years, to October 13, 2023.

Key Points: 
  • The term of the line of credit was also extended by two years, to October 13, 2023.
  • We have had the pleasure of working with the CareCloud team since 2017 and have witnessed their tremendous growth over the years, said Tom Gordon, Managing Director of Life Science and Healthcare at Silicon Valley Bank.
  • We appreciate Silicon Valley Bank's partnership and belief in our business model.
  • For 35 years, Silicon Valley Bank (SVB) has helped innovative companies and their investors move bold ideas forward, fast.

ProPhase Labs to Present at the Benzinga Healthcare Small Cap Conference

Wednesday, September 22, 2021 - 1:30pm

GARDEN CITY, NY, Sept. 22, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (Nasdaq: PRPH), a diversified biotech and genomics company, announces today that Chairman and CEO Ted Karkus will present at the Benzinga Healthcare Small Cap Conference, which is being held virtually from September 29 30, 2021.

Key Points: 
  • GARDEN CITY, NY, Sept. 22, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (Nasdaq: PRPH), a diversified biotech and genomics company, announces today that Chairman and CEO Ted Karkus will present at the Benzinga Healthcare Small Cap Conference, which is being held virtually from September 29 30, 2021.
  • ProPhase Precision Medicine, Inc., focuses on genomics testing technologies, a comprehensive method for analyzing entire genomes, including the genes and chromosomes in DNA.
  • ProPhase Global Healthcare, Inc. was formed to seek to expand the Companys SARS-CoV-2 (COVID-19) testing into other countries and to pursue additional healthcare-related initiatives.
  • ProPhase Labs has decades of experience researching, developing, manufacturing, distributing, marketing, and selling OTC consumer healthcare products and dietary supplements, including dietary supplements under the TK Supplements brand.

Biocept Implements COVID-19 Testing Program at Select California Community Colleges, Supporting Testing Needs for Students and Staff Amid Pandemic

Wednesday, September 22, 2021 - 1:17pm

Since launching SARS-CoV-2 testing services for customers in June 2020, the company has received more than 570,000 samples for processing.

Key Points: 
  • Since launching SARS-CoV-2 testing services for customers in June 2020, the company has received more than 570,000 samples for processing.
  • Many California community colleges have established COVID-19 vaccine and testing policies for students and staff.
  • To support these efforts, Biocept is providing PCR-based COVID-19 testing services that include conveniently located onsite sample collection at college campuses.
  • Biocept began offering COVID-19 testing to California community colleges in April 2021, due to its partnership with the Foundation of California Community Colleges and the CollegeBuys program.

Schools Use Elementary and Secondary Emergency Relief Funds on Proven UV-C Lighting Technology

Wednesday, September 22, 2021 - 2:00pm

INVZBL, a technology company specializing in UV-C disinfection products designed in the United States, offers public, private and charter schools the opportunity to spend Elementary and Secondary School Emergency Relief (or ESSER III) funds on proven technology solutions to keep students safe this school year.

Key Points: 
  • INVZBL, a technology company specializing in UV-C disinfection products designed in the United States, offers public, private and charter schools the opportunity to spend Elementary and Secondary School Emergency Relief (or ESSER III) funds on proven technology solutions to keep students safe this school year.
  • Last March, a third pandemic stimulus bill called the American Rescue Plan was signed into law, providing public school districts $122 billion in ESSER III funds.
  • Through the American Rescue Plan, schools have a tremendous opportunity to invest in solutions that help stop the spread of airborne viruses.
  • Once deployed and operational, our technology offers customers a peace-of-mind they cannot find anywhere else.

Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern

Wednesday, September 22, 2021 - 12:00pm

The Vietnam Ministry of Health has reviewed the safety data following both injections in the Phase 1 part of the study and has given permission to proceed with enrollment of Phase 2 and Phase 3a.

Key Points: 
  • The Vietnam Ministry of Health has reviewed the safety data following both injections in the Phase 1 part of the study and has given permission to proceed with enrollment of Phase 2 and Phase 3a.
  • Emergency Use Authorization filing in Vietnam could be as soon as December 2021.
  • The tolerability profile of ARCT-154 in the Phase 1 study was favorable.
  • We are very pleased, together with our partner Vinbiocare, to have rapidly completed enrollment and dosing of the ARCT-154 Phase 1 study, and to receive approval to proceed into Phase 2/3a.